Get startedLog in
    Picture of ExpreS2ion Biotech Holding AB logo

    EXPRS2 — ExpreS2ion Biotech Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: ExpreS2ion Biotech: Approval And Initiation Of COVID-19 Clinical Phase I/II Study For The ABNCoV2 Vaccine

    Picture of ExpreS2ion Biotech Holding AB logoExpreS2ion Biotech Holding AB
    08/03/2021 10:05
    March 8 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * APPROVAL AND INITIATION OF THE COVID-19 CLINICAL PHASE
I/II
STUDY FOR THE ABNCOV2 VACCINE
    * CLINICAL STUDY IS NOW STARTING WITH ENROLMENT OF UP TO 42
STUDY
PARTICIPANTS TO INVESTIGATE SAFETY AND SECONDARY EFFICACY
PARAMETERS
    * FIRST HUMAN DOSING IS PLANNED FOR MARCH 12, 2021
    * CTA APPROVAL IS IN LINE WITH PLANS TO PRESENT INITIAL
CLINICAL
PHASE I/IIA RESULTS IN Q1 2021


Source text for Eikon:  ID:nWkrdnYwZ 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on ExpreS2ion Biotech Holding AB

    See all news